Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Novacyt

Market Cap 29.71M 34.47M 27.34M 25.65M 48.18M 3.26B 48.66M 323M 126M 1.6B 129M 127M 5.52B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 31.67M 36.74M 29.14M 27.34M 51.35M 3.47B 51.87M 345M 135M 1.7B 138M 135M 5.88B EV / Sales 2026 *
1.04x
EV / Sales 2027 * 0.99x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.73%
1 week-5.46%
Current month-31.02%
1 month-21.88%
3 months+5.03%
6 months-5.79%
Current year+4.09%
1 week 0.39
Extreme 0.39
0.46
1 month 0.39
Extreme 0.39
0.7
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap.
03-29Buy

Chief Executive Officer

15,149 0.0214%
03-29Buy

Chairman

1,802 0.0026%
03-29Buy

Chief Executive Officer

56,438 0.0799%
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%-5.46%-18.92%-11.75% 34.47M
-0.41%-1.35%-38.90%-36.13% 548M
-3.99%+7.33%+256.14% - 528M
-1.66%+8.43%-32.74%+26.00% 142M
-4.82%-12.98%+48.24%+80.98% 125M
Average -2.39%-3.90%+42.76%+14.78% 275.66M
Weighted average by Cap. -2.35%-0.66%+83.26%-7.49%

Financials

2026 *2027 *
Net sales 30.52M 35.42M 28.09M 26.35M 49.51M 3.35B 50M 332M 130M 1.64B 133M 130M 5.67B 34.86M 40.45M 32.08M 30.1M 56.54M 3.82B 57.1M 379M 148M 1.87B 152M 149M 6.48B
Net income - -
Net Debt 1.96M 2.27M 1.8M 1.69M 3.17M 214M 3.2M 21.28M 8.31M 105M 8.52M 8.34M 363M 4.84M 5.62M 4.46M 4.18M 7.85M 531M 7.93M 52.68M 20.58M 260M 21.08M 20.64M 900M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-06-16 0.4070 -0.73% 78,250
26-06-15 0.4100 -2.84% 212,352
26-06-12 0.4220 +2.93% 264,754
26-06-11 0.4100 -2.38% 359,298
26-06-10 0.4200 -2.44% 529,702

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!